Science Corporation Raises $400M for Vision Chip PRIMA
By Ganesh Karki
Key facts
- Section
- Tech & AI
- Country
- Global
- Published
- 22 Nov 2026
Science Corporation said on 17 November it has raised $400 million in a Series D funding round to commercialise its PRIMA vision-restoration system in Europe and prepare for a launch in the United States. The round brings the neurotechnology company total funding since its founding in 2021 to more than $900 million.
| Organisation | Science Corporation |
What the Science Corporation funding is for
PRIMA is a wearable and implantable chip system designed to restore some form vision for people with late-stage macular degeneration. It received a European CE mark and launched in Europe in July 2026, and is now available in Germany. In a single-arm clinical trial of 38 patients, PRIMA restored central vision in patients with geographic atrophy, a form of age-related macular degeneration. Science aims to reach the United States market through the Humanitarian Device Exemption pathway, and is also trialling PRIMA in patients with Stargardt disease, a separate inherited condition that causes progressive vision loss. The Series D backers include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. No lead investor was named. Readers can also read our report on the Microsoft AI diagnostic orchestrator, and more health technology news in our Tech section.
What it means
The raise comes eight months after a $230 million Series C in March, and it funds both the commercial rollout of a product that already has patients in Europe and the more experimental bio-hybrid work that is Science longer-term aim: a sensor built from cultured neurons and silicon, designed to connect living neural tissue directly with computing systems. TechCrunch reported, citing a person familiar with the deal, that investors valued the company at $3.5 billion in the round. Science own announcement did not state a valuation. The company was founded in 2021 by Max Hodak, the former president of Neuralink.
What the sources do not say
Science has not published patient counts, revenue or headcount for PRIMA, and the sources give no date for a United States launch. The $3.5 billion valuation comes from an unnamed source rather than the company, and should be read as reported rather than confirmed. The sources also do not say how many patients PRIMA has treated in Europe since its July launch, or when the bio-hybrid sensor might reach human trials.
Sources: MedTech Dive, the $400 million round, the CE mark and the 38-patient trial; TechCrunch, the reported $3.5 billion valuation and the investor list; GlobalData, the European rollout and the total funding above $900 million.
Frequently asked questions
What is PRIMA?
Where is PRIMA available?
How much has Science Corporation raised in total?
Sources and references
Information checked: 22 November 2026
Related stories
US Smartphone Shipments Fall 9% as Apple Hits 57% Share
US smartphone shipments fell 9% in Q3 2026, as memory constraints hit low-end Android. Apple was the only maker to grow, reaching a 57% share.
22 November 2026Claude Solves Two Black Hole Physics Problems, Anthropic Says
Claude black hole physics results solved two open problems, Anthropic said on 17 November, finishing a 2003 calculation and finding an exact limit.
22 November 2026OpenAI GPT-Live-1.1 Cuts Idle Voice Agent Costs by 60%
OpenAI GPT-Live-1.1 is now in the API with a standby mode that bills idle WebRTC time at $0.02 a minute, 60% less than the $0.05 active rate for voice agents.
22 November 2026Apple Creator Studio Adds AI Assistants Across Final Cut and Logic
The Apple Creator Studio update adds AI assistants across Final Cut Pro, Logic Pro, Pixelmator Pro and iWork, rolling out from 18 November.